As the initial surge of the COVID-19 pandemic subsides, Massachusetts General Hospital leaders are discussing the transition to strategies for recovery and wellness.
Different “Subtypes” of Alzheimer’s may be Linked to Different Modifications of the Tau Protein, Mass General-Led Team Finds
A new study reveals a possible biological reason that Alzheimer’s Disease progresses at different rates in different patients.
Two years ago, Sean M. Healey became a part of the Mass General ALS family and an advocate for those with ALS. We are saddened to share the news that Sean M. Healey, our treasured partner, patient and friend passed away peacefully May 26, 2020 with his loving family by his side.
Peer-reviewed results of a trial led by the Healey Center’s Dr. Sabrina Paganoni, will be published soon. The CENTAUR trial, highlighted in a Wall Street Journal article, tested a drug that showed promise in slowing muscle decline in individuals with ALS.
Reprogramming a patient’s own skin cells to replace cells in the brain that are progressively lost during Parkinson’s disease (PD) has been shown to be technically feasible, reports a team of investigators from McLean Hospital and Massachusetts General Hospital in the most recent issue of The New England Journal of Medicine.
Mass General Researchers Link High Calcium Levels in Mitochondria to Neuronal Death in Alzheimer’s Disease
This relationship was previously documented in cell culture, but seeing this phenomenon in living mice makes it more likely that this occurs in people also and could point to a new target for Alzheimer’s disease.
In this Q&A, Aneesh Singhal, MD, vice chair of the Department of Neurology, describes the risk of clotting disorders among COVID-19 patients, the treatment options available, how patients can prevent stroke and what to do if they experience symptoms.
The Healey Center International Prize for Innovation in ALS is an annual global prize celebrating excellence in research for a team of investigators who catalyse exceptional discoveries leading to a transformative advance in therapy development in ALS.
Aquí hay algunas respuestas a preguntas frecuentes sobre cómo el brote del COVID-19 puede afectar su tratamiento de ELA.
Please join us for a conversation about the HEALEY ALS Platform Trial on Wednesday, April 8 at 3:00 pm.
The Patient Gateway provides secure online access to your health information whenever you need it. Check upcoming appointments, communicate with your doctor’s office, review medications and pay medical bills—all seamlessly online 24/7.